CompletedPhase 2NCT00576836
Thymus Transplantation Dose in DiGeorge #932
Studying 22q11.2 deletion syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sumitomo Pharma Switzerland GmbH
- Principal Investigator
- M. Louise Markert, MD, PhDDuke University Medical Center, Pediatrics, Allergy & Immunology
- Intervention
- Cultured Thymus Tissue Implantation (CTTI)(biological)
- Enrollment
- 7 enrolled
- Eligibility
- All sexes
- Timeline
- 2004 – 2019
Study locations (1)
- Duke University Medical Center, Durham, North Carolina, United States
Collaborators
National Institutes of Health (NIH) · National Institute of Allergy and Infectious Diseases (NIAID) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00576836 on ClinicalTrials.govOther trials for 22q11.2 deletion syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05664412Using Transcranial Alternating Current Stimulation to Improve Executive Function in 22q11.2 Deletion SyndromeStephan Eliez
- RECRUITINGNCT05924347Early Scoliotic Changes in Children at Increased Risk for Scoliosis DevelopmentUMC Utrecht
- RECRUITINGNCT05329935Congenital Athymia Patient RegistrySumitomo Pharma Switzerland GmbH
- RECRUITINGNANCT04639388Understanding of Psychotic Disorders in Children With 22q11.2DSHôpital le Vinatier
- RECRUITINGNCT00556530Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion SyndromeAlbert Einstein College of Medicine